Claims:

1. A compound of formula (Ia)



(Ia)

wherein R^1, R^2, R^3, and R^4 independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl, C_{1-12}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC_{1-12}-alkyl, amino, acylamino, C_{1-12}-alkylamino, arylamino, aralkylamino, aminoC_{1-12}-alkyl, C_{1-12}-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C_{1-12}-alkoxyC_{1-12}-alkyl, aryloxyC_{1-12}-alkyl, aralkoxyC_{1-12}-alkyl, C_{1-12}-alkylthio, thioC_{1-12}-alkyl, C_{1-12}-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR^{11}, or -SO_2R^{12}, wherein R^{11} and R^{12} independently of each other are selected from hydroxy, halogen, perhalomethyl, C_{1-6}-alkoxy or amino optionally substituted with one or more C_{1-6}-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
or R^1 and R^2, R^2 and R^3 and/or R^3 and R^4 may form a cyclic ring containing from 5 to 7 carbon atoms optionally substituted with one or more C_{1-6}-alkyl;

ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl, C_{1-12}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC_{1-12}-alkyl, amino, acylamino, C_{1-12}-alkylamino, arylamino, aralkylamino, aminoC_{1-12}-alkyl, C_{1-12}-alkoxycarbonyl, aryloxycarbonyl,

aralkoxycarbonyl, C_{1-12}-alkoxyC_{1-12}-alkyl, aryloxyC_{1-12}-alkyl, aralkoxyC_{1-12}-alkyl, C_{1-12}-alkylthio, thioC_{1-12}-alkyl, C_{1-12}-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR^{11}, or -SO_2R^{12}, wherein R^{11} and R^{12} independently of each other are selected from hydroxy, halogen, perhalomethyl, C_{1-6}-alkoxy or amino optionally substituted with one or more C_{1-6}-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

X is a valence bond, -(CHR^9)-, -(CHR^9)-CH_2-, -CH=CH-, -O-(CHR^9)-, -S-(CHR^9)-, -(NR^9)-CH_2-, -(CHR^9)-CH=CH-, -(CHR^9)-CH_2-CH_2-, -(C=O)-, -O-CH_2-O-, -(NR^9)-$S(O_2)$-, -CH=(CR^9)-, -(CO)-(CHR^9)-, -CH_2-(SO)-, -(SO)-, -(SO_2)-, -CH_2-(SO_2)-, -CH_2-O-CH_2-, wherein R^9 is hydrogen, halogen, hydroxy, nitro, cyano, formyl, C_{1-12}-alkyl, C_{1-12}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, C_{1-12}-alkylamino, arylamino, aralkylamino, aminoC_{1-12}-alkyl, C_{1-12}-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C_{1-12}-alkoxyC_{1-12}-alkyl, aryloxyC_{1-12}-alkyl, aralkoxyC_{1-12}-alkyl, C_{1-12}-alkylthio, thioC_{1-12}-alkyl, C_{1-12}-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR^{13}, or -SO_2R^{14}, wherein R^{13} and R^{14} independently of each other are selected from hydroxy, halogen, C_{1-6}-alkoxy, amino optionally substituted with one or more C_{1-6}-alkyl, perhalomethyl or aryl;

Ar represents arylene, heteroarylene, or a divalent heterocyclic group optionally substituted with one or more C_{1-6}-alkyl or aryl;

R^5 represents hydrogen, hydroxy, halogen, C_{1-12}-alkoxy, C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R^5 forms a bond together with R^6,

R^6 represents hydrogen, hydroxy, halogen, C_{1-12}-alkoxy, C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl, acyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R^6 forms a bond together with R^5,

R^7 represents hydrogen, C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl, aryl, aralkyl, C_{1-12}-alkoxyC_{1-12}-alkyl, C_{1-12}-alkoxycarbonyl, aryloxycarbonyl, C_{1-12}-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

R^8 represents hydrogen, C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

20080204 1007754.1

Y represents oxygen, sulphur or NR^{10}, where R^{10} represents hydrogen, C_{1-12}-alkyl, aryl, hydroxyC_{1-12}-alkyl or aralkyl groups or when Y is NR^{10}, R^8 and R^{10} may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C_{1-6}-alkyl;
n is an integer ranging from 1 to 4 and m is an integer ranging from 0 to 1;
or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R^1, R^2, R^3, and R^4 independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C_{1-7}-alkyl, C_{4-7}-alkenynyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC_{1-7}-alkyl, amino, acylamino, C_{1-7}-alkylamino, arylamino, aralkylamino, aminoC_{1-7}-alkyl, C_{1-7}-alkoxyC_{1-7}-alkyl, aryloxyC_{1-7}-alkyl, aralkoxyC_{1-7}-alkyl, C_{1-7}-alkylthio, thioC_{1-7}-alkyl, C_{1-7}-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, $-COR^{11}$, or $-SO_2R^{12}$, wherein R^{11} and R^{12} independently of each other are selected from hydroxy, perhalomethyl or amino optionally substituted with one or more C_{1-6}-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano;
or R^1 and R^2, R^2 and R^3 and/or R^3 and R^4 may form a cyclic ring containing from 5 to 7 carbon atoms optionally substituted with one or more C_{1-6}-alkyl.

3. A compound according to anyone of the preceding claims wherein R^1, R^2, R^3, and R^4 independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C_{1-7}-alkyl, C_{4-7}-alkenynyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, amino, acylamino, C_{1-7}-alkylamino, arylamino, aralkylamino, aminoC_{1-7}-alkyl, C_{1-7}-alkoxyC_{1-7}-alkyl, aryloxyC_{1-7}-alkyl, aralkoxyC_{1-7}-alkyl, C_{1-7}-alkylthio, thioC_{1-7}-alkyl; optionally substituted with one or more halogen or hydroxy.

4. A compound according to anyone of the preceding claims wherein R^1, R^2, R^3, and R^4 independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy or C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaryloxy, heteroaralkoxy, acyl, arylamino, aryloxyC_{1-7}-alkyl.

20080204:160759

5. A compound according to anyone of the preceding claims wherein R^1, R^2, R^3, and R^4 independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy , C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy or aryl.

6. A compound according to anyone of the preceding claims wherein R^1, R^2, R^3 and R^4 independently of each other represent hydrogen, halogen or phenyl.

7. A compound according to anyone of the preceding claims wherein ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C_{1-7}-alkyl, C_{4-7}-alkenynyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC_{1-7}-alkyl, amino, acylamino, C_{1-7}-alkylamino, arylamino, aralkylamino, aminoC_{1-7}-alkyl, C_{1-7}-alkoxyC_{1-7}-alkyl, aryloxyC_{1-7}-alkyl, aralkoxyC_{1-7}-alkyl, C_{1-7}-alkylthio, thioC_{1-7}-alkyl, C_{1-7}-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, $-COR^{11}$, or $-SO_2R^{12}$, wherein R^{11} and R^{12} independently of each other are selected from hydroxy, perhalomethyl or amino optionally substituted with one or more C_{1-6}-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano.

8. A compound according to anyone of the preceding claims wherein ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C_{1-7}-alkyl, C_{4-7}-alkenynyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, amino, acylamino, C_{1-7}-alkylamino, arylamino, aralkylamino, aminoC_{1-7}-alkyl, C_{1-7}-alkoxyC_{1-7}-alkyl, aryloxyC_{1-7}-alkyl, aralkoxyC_{1-7}-alkyl, C_{1-7}-alkylthio, thioC_{1-7}-alkyl; optionally substituted with one or more halogen or hydroxy.

9. A compound according to anyone of the preceding claims wherein ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy or C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaryloxy, heteroaralkoxy, acyl, arylamino, aryloxyC_{1-7}-alkyl.

20080204 1007459.1

10. A compound according to anyone of the preceding claims wherein ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy or C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy or aryl.

11. A compound according to anyone of the preceding claims wherein ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen or phenyl.

12. A compound according to anyone of the preceding claims wherein X is a valence bond, -(CHR^9)-, -(CHR^9)-CH_2-, -CH=CH-, -O-(CHR^9)-, -S-(CHR^9)-, -(NR^9)-CH_2-, -(CHR^9)-CH=CH-, -(CHR^9)-CH_2-CH_2-, -(C=O)-, -O-CH_2-O-, -(NR^9)-S(O_2)-, -CH=(CR^9)-, -(CO)-(CHR^9)-, -CH_2-(SO)-, -(SO)-, -(SO_2)-, -CH_2-(SO_2)-, -CH_2-O-CH_2-, wherein R^9 is hydrogen, halogen, hydroxy, cyano, C_{1-7}-alkyl, C_{1-7}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, C_{1-7}-alkylamino, arylamino, aralkylamino, aminoC_{1-7}-alkyl, C_{1-7}-alkoxyC_{1-7}-alkyl, aryloxyC_{1-7}-alkyl, aralkoxyC_{1-7}-alkyl, C_{1-7}-alkylthio or thioC_{1-7}-alkyl.

13. A compound according to anyone of the preceding claims wherein X is a valence bond, -(CHR^9)-, -(CHR^9)-CH_2-, -CH=CH-, -O-(CHR^9)-, -S-(CHR^9)-, -(NR^9)-CH_2-, -(CHR^9)-CH=CH-, -(CHR^9)-CH_2-CH_2-, -(C=O)-, -O-CH_2-O-, -(NR^9)-S(O_2)-, -CH=(CR^9)-, -(CO)-(CHR^9)-, -CH_2-(SO)-, -(SO)-, -(SO_2)-, -CH_2-(SO_2)-, -CH_2-O-CH_2-, wherein R^9 is hydrogen, halogen, hydroxy, C_{1-7}-alkyl, C_{1-7}-alkoxy or aryl.

14. A compound according to anyone of the preceding claims wherein X is a valence bond, -(CHR^9)-, -(CHR^9)-CH_2-, -CH=CH-, -O-(CHR^9)-, -S-(CHR^9)-, -(NR^9)-CH_2-, -(CHR^9)-CH=CH-, -(CHR^9)-CH_2-CH_2-, -(C=O)-, -O-CH_2-O-, -(NR^9)-S(O_2)-, -CH=(CR^9)-, -(CO)-(CHR^9)-, -CH_2-(SO)-, -(SO)-, -(SO_2)-, -CH_2-(SO_2)-, -CH_2-O-CH_2-, wherein R^9 is hydrogen, halogen, hydroxy, C_{1-4}-alkyl or C_{1-4}-alkoxy.

15. A compound according to anyone of the preceding claims wherein X is a valence bond, -(CHR^9)-, -(CHR^9)-CH_2-, -CH=CH-, -O-(CHR^9)-, -(CHR^9)-CH=CH-, -(CHR^9)-CH_2-CH_2-, -(C=O)-, -O-CH_2-O-, -CH=(CR^9)-, -(CO)-(CHR^9)-, -CH_2-(SO)-, -(SO)-, -(SO_2)-, -CH_2-(SO_2)-, -CH_2-O-CH_2-, wherein R^9 is hydrogen.

16. A compound according to anyone of the preceding claims wherein Ar represents arylene, heteroarylene, or a divalent heterocyclic group optionally substituted with one or more C_{1-6}-alkyl or aryl;

R^5 represents hydrogen, hydroxy, halogen, C_{1-7}-alkoxy, C_{1-7}-alkyl, C_{4-7}-alkenynyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl; or R^5 forms a bond together with R^6,

R^6 represents hydrogen, hydroxy, halogen, C_{1-7}-alkoxy, C_{1-7}-alkyl, C_{4-7}-alkenynyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl; or R^6 forms a bond together with R^5,

R^7 represents hydrogen, C_{1-7}-alkyl, C_{4-7}-alkenynyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, aryl, aralkyl, C_{1-7}-alkoxyC_{1-7}-alkyl, C_{1-7}-alkoxycarbonyl, aryloxycarbonyl, C_{1-7}-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups;

R^8 represents hydrogen, C_{1-7}-alkyl, C_{4-7}-alkenynyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl.

Y represents oxygen, sulphur or NR^{10}, where R^{10} represents hydrogen, C_{1-7}-alkyl, hydroxyC_{1-7}-alkyl;

n is an integer ranging from 2 to 3 and m is an integer ranging from 0 to 1.

17. A compound according to anyone of the preceding claims wherein Ar represents arylene or heteroarylene;

R^5 represents hydrogen, hydroxy, halogen; or R^5 forms a bond together with R^6,

R^6 represents hydrogen, hydroxy, halogen; or R^6 forms a bond together with R^5,

R^7 represents hydrogen, C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, aryl, aralkyl, C_{1-7}-alkoxyC_{1-7}-alkyl, C_{1-7}-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups;

R^8 represents hydrogen, C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl;

Y represents oxygen or sulphur;

n is an integer ranging from 2 to 3 and m is 1.

18. A compound according to anyone of the preceding claims wherein Ar represents arylene or heteroarylene;

R^5 represents hydrogen;

R^6 represents hydrogen;

R^7 represents hydrogen, C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, aryl, aralkyl, C_{1-7}-alkoxyC_{1-7}-alkyl;

20080204 15:07:01

R^8 represents hydrogen, C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl;
Y represents oxygen;
n is an integer ranging from 2 to 3 and m is 1.

19. A compound according to anyone of the preceding claims wherein Ar represents arylene
R^5 represents hydrogen;
R^6 represents hydrogen;
R^7 represents hydrogen, C_{1-4}-alkyl, C_{2-4}-alkenyl, C_{2-4}-alkynyl,
R^8 represents hydrogen, C_{1-4}-alkyl,
Y represents oxygen;
n is an integer ranging from 2 to 3 and m is 1.

20. A compound according to anyone of the preceding claims wherein Ar represents phenylene,
R^5 represents hydrogen;
R^6 represents hydrogen;
R^7 represents hydrogen, C_{1-4}-alkyl,
R^8 represents hydrogen
Y represents oxygen;
n is an integer ranging from 2 to 3 and m is 1.

21. A compound according to anyone of the preceding claims wherein A is benzo optionally substituted with one or more halogen or phenyl.

22. A compound according to anyone of the preceding claims wherein A is pyrido.

23. A compound according to anyone of the preceding claims wherein Ar is arylene.

24. A compound according to anyone of the preceding claims wherein X is $-(CHR^9)-CH_2-$, wherein R^9 is H.

25. A compound according to anyone of the preceding claims wherein X is -CH=CH-.

26. A compound according to anyone of the preceding claims wherein X is -(SO)-.

20020154A1 20021024

27. A compound according to anyone of the preceding claims wherein X is $-O-CH_2-O-$.

28. A compound according to anyone of the preceding claims wherein X is a valence bond.

29. A compound according to anyone of the preceding claims X is $-O-CH_2-$.

30. A compound according to anyone of the preceding claims wherein X is $-(CHR^9)-CH_2-CH_2$, wherein R^9 is H.

31. A compound according to anyone of the preceding claims wherein X is $-(CO)-(CHR^9)-$, wherein R^9 is H.

32. A compound according to anyone of the preceding claims wherein X is $-CH=(CR^9)-$, wherein R^9 is C_{1-12}-alkoxy, preferably methoxy.

33. A compound according to anyone of the preceding claims wherein X is $-(NR^9)-S(O_2)-$, wherein R^9 is C_{1-12}-alkyl, preferably methyl.

34. A compound according to anyone of the preceding claims wherein X is -(C=O)-.

35. A compound according to anyone of the preceding claims wherein R^1, R^2, R^3 and R^4 are H.

36. A compound according to anyone of the preceding claims wherein n is 2.

37. A compound according to anyone of the preceding claims wherein n is 3.

38. A compound according to anyone of the preceding claims wherein m is 1.

39. A compound according to anyone of the preceding claims wherein R^5 is H.

40. A compound according to anyone of the preceding claims wherein R^6 is H.

41. A compound according to anyone of the preceding claims wherein R^7 is ethyl.

42. A compound according to anyone of the preceding claims wherein R^8 is H.

43. A compound according to anyone of the preceding claims wherein R^8 is ethyl.

44. A compound according to anyone of the preceding claims wherein Y is oxygen.

45. The compound according to claim 1 which is

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-methoxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-propoxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-benzyloxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-methoxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-2-ethoxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-2-methoxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-methoxy]-phenyl}-2-ethoxy-propionic acid,

2-Ethoxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-propionic acid,

2-Methoxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-propionic acid,

2-Propoxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-propionic acid,

2-Benzyloxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-propionic acid,

2-Ethoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propoxy]-phenyl)-propionic acid,

2-Methoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propoxy]-phenyl)-propionic acid,

2-Benzyloxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propoxy]-phenyl)-propionic acid,

2-Ethoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propyl]-phenyl)-propionic acid,

20020-4550.07

2-Methoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propyl]-phenyl)-propionic acid,

2-Benzyloxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propyl]-phenyl)-propionic acid,

2-Ethoxy-3-(4-[1-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-methoxy]-phenyl)-propionic acid,

3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,

3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-propoxy-propionic acid,

3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-methoxy-propionic acid,

3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-benzyloxy-propionic acid,

3-{4-[1-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-methoxy]-phenyl}-2-ethoxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propoxy]-phenyl}-2-methoxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propoxy]-phenyl}-2-benzyloxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propyl]-phenyl}-2-ethoxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propyl]-phenyl}-2-methoxy-propionic acid,

3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propyl]-phenyl}-2-benzyloxy-propionic acid,

2-Ethoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-methoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

10820 PCT

2-Methoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-methoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

20080274597.1 20080820

2-Ethoxy-3-{4-[1-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-methoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[a,*d*]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(9-oxo-9*H*-acridin-10-yl)-methoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[2-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,

1007574-020802

2-Methoxy-3-{4-[3-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,
2-Benzyloxy-3-{4-[3-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,
2-Ethoxy-3-{4-[3-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,
2-Propoxy-3-{4-[3-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,
2-Methoxy-3-{4-[3-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,
2-Benzyloxy-3-{4-[3-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,
2-Ethoxy-3-{4-[1-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-methoxy]-phenyl}-propionic acid,
3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
3-(4-(1-(2-Chloro-5-oxo-phenothiazin-10-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-methoxy-propionic acid,
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-propoxy-propionic acid,
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-methoxy-propionic acid,
3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,
(S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
(S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
(S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
(S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
(S)-3-(4-(1-(Betacarbolin-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
(S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,
(S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-methoxy-propionic acid,
(S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,
(S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,
(S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,
(S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-methoxy-propionic acid,
(S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-propoxy-propionic acid,
(S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,
3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,

2008201955 20 Mar 2008

3-(4-(2-(Dibenzo[*b*,*f*]azepin-5-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
3-(4-(2-(Dibenzo[*b*,*f*]azepin-5-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
3-(4-(2-(Dibenzo[*b*,*f*]azepin-5-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
3-(4-(2-(Dibenzo[*b*,*f*]azepin-5-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
3-(4-(1-(Dibenzo[*b*,*f*]azepin-5-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
3-(4-(3-(Dibenzo[*b*,*f*]azepin-5-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,
3-(4-(3-(Dibenzo[*b*,*f*]azepin-5-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,
3-(4-(3-(Dibenzo[*b*,*f*]azepin-5-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,
3-(4-(3-(Dibenzo[*b*,*f*]azepin-5-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,
3-(4-(3-(Dibenzo[*b*,*f*]azepin-5-yl)-propyl)-phenyl)-2-propoxy-propionic acid,
3-(4-(3-(Dibenzo[*b*,*f*]azepin-5-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,
3-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-propoxy)-phenyl-2-ethoxy-propionic acid,
3-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-propoxy)-phenyl-2-methoxy-propionic acid,
3-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-propoxy)-phenyl-2-propoxy-propionic acid,
3-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-propoxy)-phenyl-2-benzyloxy-propionic acid,
3-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-propyl)-phenyl-2-ethoxy-propionic acid,
3-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-propyl)-phenyl-2-methoxy-propionic acid,
3-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-propyl)-phenyl-2-propoxy-propionic acid,
3-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-propyl)-phenyl-2-benzyloxy-propionic acid,
2-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-ethoxy)-phenyl-2-ethoxy-propionic acid,
2-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-ethoxy)-phenyl-2-propoxy-propionic acid,
1-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-methoxy)-phenyl-2-ethoxy-propionic acid,
2-(4-Dibenzo[d,g]dioxazocin-12-yl)-1-ethoxy)-phenyl-2-benzyloxy-propionic acid,
(S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
(S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
(S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
(S) 3-(4-(1-(3-Phenyl-carbazol-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(3-(3-Phenyl-carbazol-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(3-(3-Phenyl-carbazol-9-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(2-(3-Benzyl-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
(S)3-(4-(2-(3-(2-Pyridyl)-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(2-(3-(3-Furanyl)l-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(2-(3-(2-thionyl)-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,

2008204559 20 Jul 2011

(S) 3-(4-(2-(3-Bromo-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(2-(3-Bromo-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
(S) 3-(4-(2-(3-Bromo-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
(S) 3-(4-(1-(3-Bromo-carbazol-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(3-(3-Bromo-carbazol-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid
(S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
(S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
(S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
(S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
(S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
(S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
(S) 3-(4-(1-(3,6 Dibromo-carbazol-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(3-(3,6 Dibromo-carbazol-9-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(3-(3,6 Dibromo-carbazol-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-methoxy-propionic acid,
(S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-propoxy-propionic acid,
(S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
(S) 3-(4-(1-Carbazol-9-yl-methoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(3-Carbazol-9-yl-propoxy)-phenyl)-2-ethoxy-propionic acid,
(S) 3-(4-(3-Carbazol-9-yl-propyl)-phenyl)-2-ethoxy-propionic acid;
or a pharmaceutically acceptable salt thereof.

46. The compound according to claim 1 which is
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,
2-Ethoxy-3-{4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl}-propionic acid,
3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,
2-Ethoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,
2-Ethoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2007054400

2-Ethoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10λ^6-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,
2-Ethoxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,
2-Ethoxy-3-{4-[2-(5-oxo-5*H*-5λ^4-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid; or a pharmaceutically acceptable salt thereof.

47. A pharmaceutical composition comprising, as an active ingredient, a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

48. A composition according to claim 47 in unit dosage form, comprising from about 0.05 to about 100 mg, preferably from about 0.1 to about 50 mg of the compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof.

49. A pharmaceutical composition useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the composition comprising, as an active ingredient, a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

50. A pharmaceutical composition useful in the treatment and/or prevention of diabetes and/or obesity, the composition comprising, as an active ingredient, a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

51. A pharmaceutical composition for diabetes and/or obesity, the composition comprising, as an active ingredient, a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

52. A pharmaceutical composition according to anyone of the claims 47-51 for oral, nasal, transdermal, pulmonal, or parenteral administration.

53. A method for the treatment of ailments, the method comprising administering to a subject in need thereof an effective amount of a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof, or of a composition according to anyone of the preceding composition claims.

54. A method for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the method comprising administering to a subject in need thereof an effective amount of a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof, or of a composition according to anyone of the preceding claims 47-52.

55. A method for the treatment and/or prevention of diabetes and/or obesity, the method comprising administering to a subject in need thereof an effective amount of a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof, or of a composition according to anyone of the preceding claims 47-52.

56. The method according to claims 53-55, wherein the effective amount of the compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt or ester thereof is in the range of from about 0.05 to about 100 mg per day, preferably from about 0.1 to about 50 mg per day.

57. Use of a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof for the preparation of a medicament.

58. Use of a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

59. Use of a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treatment and/or prevention of diabetes and/or obesity.

20020154-5698.204

60. Use of a compound according to anyone of the preceding compound claims or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treatment and/or prevention of diabetes and obesity.

1007657v1-020902